Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 218

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection

Open access
Israel, Ariel, Shenhar, Yotam, Green, Ilan, Merzon, Eugene, Golan-Cohen, Avivit, Schäffer, Alejandro A., Ruppin, Eytan, Vinker, Shlomo, Magen, Eli · 2021 · Vaccines

Published version of a preprint

Abstract

Immune protection following either vaccination or infection with SARS-CoV-2 is thought to decrease over time. We designed a retrospective study, conducted at Leumit Health Services in Israel, to determine the kinetics of SARS-CoV-2 IgG antibodies following administration of two doses of BNT162b2 vaccine, or SARS-CoV-2 infection in unvaccinated individuals. Antibody titers were measured between 31 January 2021, and 31 July 2021 in two mutually exclusive groups: (i) vaccinated individuals who received two doses of BNT162b2 vaccine and had no history of previous infection with COVID-19 and (ii) SARS-CoV-2 convalescents who had not received the vaccine. A total of 2653 individuals fully vaccinated by two doses of vaccine during the study period and 4361 convalescent patients were included. Higher SARS-CoV-2 IgG antibody titers were observed in vaccinated individuals (median 1581 AU/mL IQR [533.8–5644.6]) after the second vaccination than in convalescent individuals (median 355.3 AU/mL IQR [141.2–998.7]; p < 0.001). In vaccinated subjects, antibody titers decreased by up to 38% each subsequent month while in convalescents they decreased by less than 5% per month. Six months after BNT162b2 vaccination 16.1% subjects had antibody levels below the seropositivity threshold of <50 AU/mL, while only 10.8% of convalescent patients were below <50 AU/mL threshold after 9 months from SARS-CoV-2 infection. This study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/vaccines10010064

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 24

  1. Khoury, 2021, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection, Nat. Med., 27, 1205, 10.1038/s41591-021-01377-8 · DOI · Paper page
  2. Kim, 2021, Looking beyond COVID-19 vaccine phase 3 trials, Nat. Med., 27, 205, 10.1038/s41591-021-01230-y · DOI · Paper page
  3. Wheatley, 2021, Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19, Nat. Commun., 12, 1162, 10.1038/s41467-021-21444-5 · DOI · Paper page
  4. Raz, 2021, One size does not fit all: Lessons from Israel’s COVID-19 vaccination drive and hesitancy, Vaccine, 39, 4027, 10.1016/j.vaccine.2021.06.004 · DOI
  5. Sampieri, 2021, SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants, Front. Immunol., 12, 701501, 10.3389/fimmu.2021.701501 · DOI · Paper page
  6. Muhsen, 2021, A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020–February 2021, Lancet Reg. Health Eur., 7, 100130, 10.1016/j.lanepe.2021.100130 · DOI
  7. Rennert, 2001, Prevalence of selected chronic diseases in Israel, Isr. Med. Assoc. J., 3, 404
  8. Hamood, 2016, A feasibility study to assess the validity of administrative data sources and self-reported information of breast cancer survivors, Isr. J. Health Policy Res., 5, 50, 10.1186/s13584-016-0111-6 · DOI
  9. Grupel, 2021, Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination, Vaccine, 39, 5337, 10.1016/j.vaccine.2021.08.025 · DOI
  10. Turner, 2021, SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses, Nature, 596, 109, 10.1038/s41586-021-03738-2 · DOI · Paper page
  11. Breuer, 2021, SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric population, Acta Paediatr., 110, 3054, 10.1111/apa.16031 · DOI
  12. Meyer, 2021, Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: A prospective longitudinal study, Clin. Microbiol. Infect., 27, 784.e1, 10.1016/j.cmi.2021.01.005 · DOI
  13. Cho, 2021, Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination, Nature, 600, 517, 10.1038/s41586-021-04060-7 · DOI · Paper page
  14. Ebinger, 2021, Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2, Nat. Med., 27, 981, 10.1038/s41591-021-01325-6 · DOI · Paper page
  15. Padoan, 2021, Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers, Clin. Chim. Acta, 519, 60, 10.1016/j.cca.2021.04.006 · DOI
  16. Cupaiolo, 2021, Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers, J. Infect., 83, 237
  17. Grobecker, 2021, SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19, Infection, 49, 739, 10.1007/s15010-021-01598-6 · DOI
  18. Schoof, 2020, An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike, Science, 370, 1473, 10.1126/science.abe3255 · DOI · Paper page
  19. Pedotti, 2021, Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice, Nature, 593, 424, 10.1038/s41586-021-03461-y · DOI
  20. Xu, 2021, Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants, Nature, 595, 278, 10.1038/s41586-021-03676-z · DOI · Paper page
  21. Iwasaki, 2016, Exploiting Mucosal Immunity for Antiviral Vaccines, Annu. Rev. Immunol., 34, 575, 10.1146/annurev-immunol-032414-112315 · DOI
  22. Li, 2021, In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies, Cell, 184, 4203, 10.1016/j.cell.2021.06.021 · DOI · Paper page
  23. Iyer, 2020, Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients, Sci. Immunol., 5, 367, 10.1126/sciimmunol.abe0367 · DOI · Paper page
  24. Hellerstein, 2020, What are the roles of antibodies versus a durable, high-quality T-cell response in protective immunity against SARS-CoV-2?, Vaccine, 6, 100076

Cited by

See all 218

Metadata

Authors
Israel, A., Shenhar, Y., Green, I., Merzon, E., Golan-Cohen, A., Schäffer, A. A., Ruppin, E., Vinker, S., & Magen, E.
Venue
Vaccines
Publisher
MDPI AG
Published
2021-12-31
Volume
10
Issue
1
Pages
64
ISSN
2076-393X (ISSN-L)
OpenAlex
W4225489846
Cited by
218
References
17
FWCI
14.66
Type
journal article
Language
en
Open access
gold
Funders
National Cancer Institute (Intramural Research program)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection. https://app.cochat.ai/papers/10.3390/vaccines10010064
The paper
Israel, A., Shenhar, Y., Green, I., Merzon, E., Golan-Cohen, A., Schäffer, A. A., Ruppin, E., Vinker, S., & Magen, E. (2021). Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection. Vaccines. https://doi.org/10.3390/vaccines10010064

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.